TOKYO -- Shares in Japanese drugmaker Eisai rose as much as 9% on Tuesday as investors took in the prospect of an earnings boost from the company's new Alzheimer's drug.
The U.S. Food and Drug Administration approved the drug lecanemab, marketed as Leqembi, under a fast-track program on Friday. The drug was developed with U.S. partner Biogen.
